Emergent BioSolutions (EBS) Misses Q4 EPS by 35c; Offers FY23 Revenue Guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.85 -1.88%
Revenue Growth %: +32.0%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
JFIN, KEQU, LASE, More
Revenue Growth %: +32.0%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.31), $0.35 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $331 million versus the consensus estimate of $297.18 million.
GUIDANCE:
Emergent BioSolutions sees FY2023 revenue of $1.15 billion, versus the consensus of $1.18 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
- AXT appoints Tracy Liu to its board of directors
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
